Better Health for All

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited cell therapies for severe diseases like hematologic malignancies and lupus.

Its entire business is devoted to developing these therapies, which aim to provide substantial health benefits. The company reported R&D expenses of $30.4 million in Q3 2024. Caribou's products, CB-010, CB-011, and CB-012, have received multiple FDA designations including Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT), indicating regulatory recognition of their potential to address unmet medical needs. The company is pursuing allogeneic CAR-T approaches, which are noted to improve access for cell therapy patients. No specific information on patent flexibility or licensing practices is provided, making it neutral.

Fair Pay & Worker Respect

Based on the available information, Caribou Biosciences' alignment with fair pay and worker respect is difficult to assess definitively. Glassdoor reviews indicate an overall employee rating of 3.7/5 and a 67% recommendation rate, suggesting a generally positive sentiment

. However, these reviews also mention concerns about internal processes, leadership, and IT management . A significant layoff of 32% of the workforce occurred, costing the company $1.8-$2 million . The CEO's compensation in 2023 was $3,116,547, but the CEO-to-median-employee pay ratio is not available . While some reviews mention good health insurance and 401k plans , there is no quantitative data on living wage coverage, pay equity, or labor violations. Given the limited data and mixed employee feedback, a conservative score of -10 is appropriate, reflecting some positive aspects but also significant data gaps and potential areas for improvement. The company size of 1-50 employees may limit the applicability of some metrics .

Fair Trade & Ethical Sourcing

No relevant data was found in the provided articles to assess Caribou Biosciences, Inc. against the 'Fair Trade & Ethical Sourcing' ethical value.

The articles explicitly state that they do not contain information pertaining to CRBU.US or the specified ethical sourcing criteria.

Kind to Animals

Caribou Biosciences conducts preclinical studies on animals, including murine models, to assess product safety and efficacy for its cell therapies.

The company's Code of Business Conduct, effective July 27, 2021, states a commitment to follow Office of Laboratory Animal Welfare (OLAW) guidelines and treat animals humanely, but this policy does not articulate measurable goals for reduction or elimination of animal testing. The company used animals in studies where PBS-treated animals became metastatic, while CAR-T cell therapies eradicated tumors. There is no evidence of non-animal testing methods being employed for product safety and efficacy. In a collaboration with Genus plc, Caribou Biosciences received a $5 million investment from Genus. Genus's overall annual R&D budget is approximately $44 million, with about 7% of sales spent on R&D, and this percentage is expected to increase by over 10% in the next financial year. The collaboration with Genus plc focuses on gene editing technology for livestock species to improve animal health and well-being, including developing PRRSv resistant pigs.

No War, No Weapons

Caribou Biosciences, Inc. is a biopharmaceutical company focused on genome-edited cell therapies. The provided articles, specifically the company's Code of Business Conduct, Scientific and Data Integrity, and Ethics, and its governance policies, do not contain specific, quantifiable evidence regarding the company's revenue from arms contracts, R&D investment in dual-use technologies with military applications, sales to embargoed regimes, peacebuilding investments, or other metrics directly related to military or conflict involvement.

While the Code of Business Conduct states an expectation for employees to comply with U.S. embargoes and export controls, there is no evidence of specific outcomes, automated controls, or percentages of compliance. The nature of the company's core business does not inherently involve weapons or military activities, and no evidence suggests otherwise. Therefore, all KPIs related to the 'No War, No Weapons' value are omitted due to a lack of specific, verifiable data points about the company's actions or performance.

Planet-Friendly Business

No specific quantitative data relevant to the Planet-Friendly Business KPIs was found in the provided articles. The articles either explicitly stated a lack of specific ESG data for Caribou Biosciences, Inc. or provided only high-level ESG risk ratings without underlying metrics.

One article mentioned a shoreline cleanup event, but this did not include measurable outcomes applicable to the quantitative KPIs.

Respect for Cultures & Communities

No specific, concrete data points were found in the provided article to assess Caribou Biosciences, Inc. against any of the KPIs for the 'Respect for Cultures & Communities' value.

The article explicitly states that no data is available and no data was found to summarize regarding this topic.

Zero Waste & Sustainable Products

The company has an asset disposal procedure in place.

It acknowledges that laws and regulations affecting its business include those covering the use and disposal of hazardous materials and environmental requirements, and expects employees, consultants, contractors, and directors to comply with all applicable environmental laws. The company relies on its Contract Manufacturing Organizations (CMOs) and suppliers to comply with regulatory requirements. There are no mentions of waste disposal violations or fines in the provided articles.